Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P13497
UPID:
BMP1_HUMAN
Alternative names:
Mammalian tolloid protein; Procollagen C-proteinase
Alternative UPACC:
P13497; A8K6F5; B2RN46; D3DSR0; Q13292; Q13872; Q14874; Q99421; Q99422; Q99423; Q9UL38
Background:
Bone morphogenetic protein 1 (BMP1), also known as Mammalian tolloid protein or Procollagen C-proteinase, is pivotal in extracellular matrix formation, influencing bone and cartilage development, muscle growth, and tissue repair. It processes precursor proteins into mature enzymes or structural components, crucial for physiological functions.
Therapeutic significance:
BMP1's involvement in Osteogenesis imperfecta 13, characterized by bone fragility and recurrent fractures, underscores its therapeutic potential. Understanding BMP1's role could open doors to innovative treatments for bone disorders and improve quality of life for affected individuals.